General Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/18/13Keryx Biopharmaceuticals Announces Issuance of U.S. Patent for Zerenex(TM) Covering Orally Administrable Forms of Ferric CitratePrinter Friendly Version
12/09/13Keryx Biopharmaceuticals to Present at the 24th Annual Oppenheimer Healthcare ConferencePrinter Friendly Version
11/08/13Keryx Biopharmaceuticals Provides Update From Ongoing Zerenex(TM) (ferric citrate coordination complex) Long-Term Safety Extension Study in Patients With Hyperphosphatemia on DialysisPrinter Friendly Version
11/05/13Keryx Biopharmaceuticals Announces Zerenex(TM) (ferric citrate coordination complex) Meets All Primary and Key Secondary Endpoints in Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients With Elevated Serum Phosphorus and Iron Deficiency AnemiaPrinter Friendly Version
11/04/13Keryx Biopharmaceuticals to Hold Conference Call Tomorrow, November 5, 2013, at 8:30AM ET to Discuss Top-Line Results from Zerenex(TM) Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients with Elevated Serum Phosphorus and Iron Deficiency AnemiaPrinter Friendly Version
11/04/13Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2013 Financial ResultsPrinter Friendly Version
10/21/13Keryx Biopharmaceuticals Announces PDUFA Goal Date for Zerenex(TM) New Drug ApplicationPrinter Friendly Version
10/17/13Keryx Biopharmaceuticals' Zerenex(TM) (Ferric Citrate Coordination Complex) Data Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2013Printer Friendly Version
10/08/13Keryx Biopharmaceuticals Announces FDA Acceptance for Filing of Zerenex(TM) New Drug ApplicationPrinter Friendly Version
10/04/13Keryx Biopharmaceuticals, Inc. Announces Appointment of Daniel P. Regan to Board of DirectorsPrinter Friendly Version
10/02/13Keryx Biopharmaceuticals Announces Appointment of Douglass H. Laidlaw, Ph.D., as Director, Medical AffairsPrinter Friendly Version
09/24/13Keryx Biopharmaceuticals to Present at BioCentury's NewsMakers in the Biotech Industry ConferencePrinter Friendly Version
09/04/13Keryx Biopharmaceuticals Announces Upcoming Corporate PresentationsPrinter Friendly Version
08/08/13Keryx Biopharmaceuticals Announces New Drug Application Submission for Zerenex™ for the Treatment of Hyperphosphatemia in Chronic Kidney Disease Patients on DialysisPrinter Friendly Version
07/31/13Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2013 Financial ResultsPrinter Friendly Version
07/30/13Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2013 Financial ResultsPrinter Friendly Version
06/03/13Keryx Biopharmaceuticals, Inc. Announces Zerenex™ Phase 3 Data Presented at the 2013 World Congress of NephrologyPrinter Friendly Version
05/07/13Keryx Biopharmaceuticals, Inc. Announces First Quarter 2013 Financial ResultsPrinter Friendly Version
05/06/13Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2013 Financial ResultsPrinter Friendly Version
03/14/13Keryx Biopharmaceuticals to Present at the 25th Annual ROTH ConferencePrinter Friendly Version
03/13/13Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical AffairsPrinter Friendly Version
03/11/13Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial ResultsPrinter Friendly Version
03/11/13Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial ResultsPrinter Friendly Version
02/22/13Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare ConferencePrinter Friendly Version
02/08/13Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ETPrinter Friendly Version
01/30/13Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common StockPrinter Friendly Version
01/29/13Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common StockPrinter Friendly Version
01/28/13Keryx Biopharmaceuticals Announces Zerenex™ (ferric citrate) Meets Primary and All Key Secondary Endpoints in Phase 3 Long-Term Study as a Treatment for Hyperphosphatemia in End-Stage Renal Disease Patients on DialysisPrinter Friendly Version
01/27/13Keryx Biopharmaceuticals to Hold Conference Call Tomorrow at 8:00 AM ET to Discuss Top-Line Results from Zerenex™ Phase 3 Long-Term StudyPrinter Friendly Version
01/07/13Keryx Biopharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version
01/07/13Keryx Biopharmaceuticals Announces Filing of New Drug Application for Marketing Approval of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco Inc.Printer Friendly Version
01/03/13Keryx Biopharmaceuticals Announces that Congress Delays Implementation of Oral-Only ESRD-Related Drugs, Including Phosphate Binders, in the Bundled ESRD Prospective Payment System by Two-Years, until January 2016Printer Friendly Version